Application of next-generation sequencing in diffuse large B-cell lymphoma

References

• 1. Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am. J. Hematol. 96(5), 617–629 (2021).
  MedlineGoogle Scholar
• 2. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503–511 (2000).
  Medline CASGoogle Scholar
• 3. He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia 35(8), 2151–2165 (2021).
  MedlineGoogle Scholar
• 4. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107(1), 265–276 (2006).
  Medline CASGoogle Scholar
• 5. Iqbal J, Naushad H, Bi C et al. Genomic signatures in B-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev. 30(2), 73–88 (2016).
  Medline CASGoogle Scholar
• 6. Zhou L, Zhao H, Shao Y et al. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. J. Cancer 12(18), 5423–5431 (2021).
  Medline CASGoogle Scholar
• 7. Sun P, Chen C, Xia Y et al. Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA. J. Cancer 10(2), 323–331 (2019).
  Medline CASGoogle Scholar
• 8. Morin RD, Mungall K, Pleasance E et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122(7), 1256–1265 (2013).
  Medline CASGoogle Scholar
• 9. Gao H, Wu B, Jin H, Yang W. A 6-lncRNA signature predicts prognosis of diffuse large B-cell lymphoma. J. Biochem. Mol. Toxicol. 35(6), 1–12 (2021).
  CASGoogle Scholar
• 10. Lodhi N, Tun M, Nagpal P et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 11(44), 4045–4073 (2020).
  MedlineGoogle Scholar
• 11. Staton AD, Koff JL, Chen Q, Ayer T, Flowers CR. Next-generation prognostic assessment for diffuse large B-cell lymphoma. Future Oncol. 11(17), 2443–2457 (2015).
  CASGoogle Scholar
• 12. Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin. Hematol. 52(2), 77–85 (2015).
  Medline CASGoogle Scholar
• 13. Klanova M, Sehn LH, Bence-Bruckler I et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood 133(9), 919–926 (2019).
  Medline CASGoogle Scholar
• 14. Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leuk. Lymphoma 63(4), 789–798 (2022).
  Medline CASGoogle Scholar
• 15. Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. Eur. J. Haematol. 97(6), 499–510 (2016).
  Medline CASGoogle Scholar
• 16. Barton S, Hawkes EA, Wotherspoon A, Cunningham D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? The Oncologist 17(12), 1562–1573 (2012).
  Medline CASGoogle Scholar
• 17. Dobashi A. Molecular pathogenesis of diffuse large B-cell lymphoma. J. Clin. Exp. Hematop. 56(2), 71–78 (2016).
  MedlineGoogle Scholar
• 18. Savage KJ, Slack GW, Mottok A et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 127(18), 2182–2188 (2016).
  Medline CASGoogle Scholar
• 19. Kano R, Masaie H, Hino A et al. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities. Diagn. Pathol. 13(1), 46 (2018).
  MedlineGoogle Scholar
• 20. Durani U, Ansell SM. CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk. Lymphoma 62(13), 3078–3086 (2021).
  Medline CASGoogle Scholar
• 21. Miyazaki K, Asano N, Yamada T et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica 105(9), 2308–2315 (2020).
  Medline CASGoogle Scholar
• 22. Xu Y, Sun W, Li F. De Novo CD5(+) Diffuse large B-cell lymphoma: biology, mechanism, and treatment advances. Clin. Lymphoma Myeloma Leuk. 20(10), e782–e790 (2020).
  MedlineGoogle Scholar
• 23. Swerdlow SH. Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology 2014(1), 90–99 (2014).
  MedlineGoogle Scholar
• 24. Mehta A, Verma A, Gupta G, Tripathi R, Sharma A. Double hit and double expresser diffuse large B cell lymphoma subtypes: discrete subtypes and major predictors of overall survival. Indian J. Hematol. Blood Transfus. 36(4), 627–634 (2020).
  MedlineGoogle Scholar
• 25. Grzegorz S. Nowakowski M, And Myron S. Czuczman, Md. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection? Oncology Educational Book (35), e449–e457 (2015).
  Google Scholar
• 26. Li J, Liu X, Yao Z, Zhang M. High-grade B-cell lymphomas, not otherwise specified: a study of 41 cases. Cancer Manag. Res. 12, 1903–1912 (2020).
  Medline CASGoogle Scholar
• 27. Ma Z, Niu J, Cao Y et al. Clinical significance of ‘double-hit’ and ‘double-expression’ lymphomas. J. Clin. Pathol. 73(3), 126–138 (2020).
  Medline CASGoogle Scholar
• 28. Yi W, Bing X, Yizhuo Z. Molecular diagnosis and treatment of relapsed/refractory diffuse large B-cell lymphoma. J. Exp. Hematol. 26(2), 603–608 (2018).
  Google Scholar
• 29. Schmitz R, Wright GW, Huang DW et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378(15), 1396–1407 (2018).
  Medline CASGoogle Scholar
• 30. Wright GW, Huang DW, Phelan JD, Coulibaly ZA. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(4), 551–568 e514 (2020).
  Medline CASGoogle Scholar
• 31. Wei X, Jinhua L. Advances in novel genotyping and molecular targeting therapy for diffuse large B cell lymphoma. J. Clin. Hematol. 33(9), 594–598 (2020).
  Google Scholar
• 32. Frontzek F, Lenz G. Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev. Clin. Pharmacol. 12(11), 1059–1067 (2019).
  Medline CASGoogle Scholar
• 33. Karmali R, Gordon LI. Molecular subtyping in diffuse large B cell lymphoma: closer to an approach of precision therapy. Curr. Treat Options Oncol. 18(2), 11 (2017).
  MedlineGoogle Scholar
• 34. Chapuy B, Stewart C, Dunford AJ. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24(5), 679–690 (2018).
  Medline CASGoogle Scholar
• 35. Zhou Z, Sehn LH, Rademaker AW et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6), 837–842 (2014).
  Medline CASGoogle Scholar
• 36. Lacy SE, Barrans SL, Beer PA et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 135(20), 1759–1771 (2020).
  Medline CASGoogle Scholar
• 37. International non-Hodgkin's lymphoma prognostic factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 329(14), 987–994 (1993).
  MedlineGoogle Scholar
• 38. Ruppert AS, Dixon JG, Salles GA, Wall A. International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. Blood 135(23), 2041–2048 (2019).
  Google Scholar
• 39. Montalban C, Diaz-Lopez A, Dlouhy I. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI. Br. J. Haematol. 176(6), 918–928 (2017).
  Medline CASGoogle Scholar
• 40. Schmitz N, Zeynalova S, Nickelsen M et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol. 34(26), 3150–3156 (2016).
  Medline CASGoogle Scholar
• 41. Wei X, Hao X, Zhou L et al. The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP. Sci. Rep. 7(1), 13592 (2017).
  MedlineGoogle Scholar
• 42. Seo S, Hong JY, Yoon S et al. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget 7(47), 76934–76943 (2016).
  MedlineGoogle Scholar
• 43. Junshik Hong SJK, Myung Hee C. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Pathology 50(1), 74–87 (2017).
  MedlineGoogle Scholar
• 44. Reddy A, Zhang J, Davis NS, Moffitt AB. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 172(2), 481–494 (2017).
  Google Scholar
• 45. Kurtz DM, Scherer F, Jin MC et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol. 36(28), 2845–2853 (2018).
  Medline CASGoogle Scholar
• 46. Younes A, Sehn LH, Johnson P et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol. 37(15), 1285–1295 (2019).
  Medline CASGoogle Scholar
• 47. Wilson WH, Wright GW, Huang DW et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39(12), 1643–1653.e1643 (2021).
  Medline CASGoogle Scholar
• 48. Dunleavy K, Pittaluga S, Czuczman MS et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113(24), 6069–6076 (2009).
  Medline CASGoogle Scholar
• 49. Chiappella A, Vitolo U. Lenalidomide in diffuse large B-cell lymphomas. Adv. Hematol. 2012, 498342 (2012).
  MedlineGoogle Scholar
• 50. Czuczman MS, Trneny M, Davies A et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin. Cancer Res. 23(15), 4127–4137 (2017).
  Medline CASGoogle Scholar
• 51. Flinn IW, Kahl BS, Leonard JP et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22), 3406–3413 (2014).
  Medline CASGoogle Scholar
• 52. Shortt J, Martin BP, Newbold A et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 121(15), 2964–2974 (2013).
  Medline CASGoogle Scholar
• 53. Johnston PB, Laplant B, Mcphail E et al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol. 3(7), e309–e316 (2016).
  MedlineGoogle Scholar
• 54. Moffitt AB, Dave SS. Clinical applications of the genomic landscape of aggressive non-Hodgkin lymphoma. J. Clin. Oncol. 35(9), 955–962 (2017).
  Medline CASGoogle Scholar
• 55. Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111(7), 3701–3713 (2008).
  Medline CASGoogle Scholar
• 56. Younes A, Romaguera J, Fanale M et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 30(33), 4161–4167 (2012).
  Medline CASGoogle Scholar
• 57. Sarkozy C, Morschhauser F, Dubois S et al. A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. Clin. Cancer Res. 26(13), 3145–3153 (2020).
  Medline CASGoogle Scholar
• 58. Sehn LH, Herrera AF, Flowers CR et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38(2), 155–165 (2020).
  Medline CASGoogle Scholar
• 59. Terui Y, Rai S, Izutsu K et al. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 112(7), 2845–2854 (2021).
  Medline CASGoogle Scholar
• 60. Kalakonda N, Maerevoet M, Cavallo F et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7(7), e511–e522 (2020).
  MedlineGoogle Scholar
• 61. Alkodsi A, Cervera A, Zhang K et al. Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. Leukemia 33(11), 2662–2672 (2019).
  MedlineGoogle Scholar
• 62. Trabucco SE, Sokol ES, Maund SL et al. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing. Future Oncol. 17(31), 4171–4183 (2021).
  CASGoogle Scholar